A new home conception kit offers health insurers a less expensive alternative to pricey fertility treatments. » Read More
Walking and cycling even in the most polluted of cities is still better for you than staying indoors, a study has shown.
A team at Oxford University have used virtual reality devices to help treat patients with paranoia, showing how VR could help health care.
Merck reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia.
JPMorgan Private Bank is rotating away from broad U.S. market exposure and making sector calls, Steven Rees says.
After the worst quarterly performance since 2002, the biotech industry could be primed to resume deal-making says one industry investor.
Obamacare is under threat from politicians. Here's how the affordable care act can work for employers, says industry veteran Denny Weinberg.
Americans want elected officials to do more to fight the growing opioid epidemic, a new survey finds.
J&J was ordered to pay $55 million to a woman who said that using the company's talc-powder products caused her to develop cancer.
Martin Shkreli made an appearance at the U.S. Federal Court in Brooklyn for a hearing related to securities fraud charges.
Pfizer has approached U.S. cancer drug maker Medivation to express interest in an acquisition, raising the possibility of a bid.
Drugmaker Biogen said on Tuesday it intends to spin off its hemophilia drug business as an independent, publicly traded company.
Pfizer reported a 19.7 percent rise in quarterly revenue, boosted by sales of its new treatments for cancer and its Hospira acquisition.
Quintiles Transnational and IMS Health said they would merge, creating a company with a market value of more than $17.6 billion.
Presentations have always been stressful, but failing tech can affect productivity and mental health, according to research into stress.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
African-Americans were much less likely to undergo potentially life-saving surgery in Georgia if they lived in heavily segregated areas.
Hedge fund manager Bill Ackman defended his key holding Valeant Pharmaceuticals on Monday, as its shares continued to tumble.
A drug company previously headed by Martin Shkreli was sued for allegedly breaching a contract that let it sell Daraprim. USA Today reports.
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
The hedge fund manager says he aims to bring a "meaningful" turnaround and touted embattled drugmaker Valeant's new chief executive.
Get the best of CNBC in your inbox